Growth Hormone

Hypothalamic-Pituitary-Somatotropic (HPS) Axis and Secretion Regulation

  • Anatomy and Cellular Basis of Growth Hormone Secretion:

    • Growth Hormone (GH), also known as somatotropin, is synthesized, stored, and secreted by somatotrophs, which are specialized endocrine cells located in the anterior pituitary gland (adenohypophysis).

    • Adenomas originating from anterior pituitary cell types occur with specific relative frequencies:

      • Lactotrope (secreting Prolactin [PRL]): 32%32\%

      • Somatotrope (secreting Growth Hormone [GH]): 21%21\%

      • Nonfunctional tumors: 25%25\%

      • Corticotrope (secreting Adrenocorticotropic Hormone [ACTH]): 13%13\%

      • Mixed Lactotrope/Somatotrope (secreting both PRL and GH): 6%6\%

      • Gonadotrope (FSH/LH) and Thyrotrope (TSH): <4%< 4\%

  • Primary Organs of the HPS Axis:

    • Hypothalamus: Acts as the primary central regulator by releasing stimulatory and inhibitory neurohormones into the hypophyseal portal system.

    • Anterior Pituitary: Responds to hypothalamic signals by secreting GH into the systemic circulation.

    • Liver: Functions as the primary target organ of GH, synthesizing and secreting Insulin-like Growth Factor-1 (IGF-1). The liver contributes approximately 75%75\% of the total circulating pool of IGF-1.

Regulation of GH secretion
  • Neurohormonal Regulation:

    • Growth Hormone-Releasing Hormone (GHRH): A hypothalamic peptide that binds to specific GHRH receptors (GHRH-R) on somatotrophs to stimulate GH synthesis and exocytosis.

    • Somatostatin / Growth Hormone-Inhibiting Hormone (GHIH / SRIF): A hypothalamic peptide that inhibits GH secretion from somatotrophs.

    • Ghrelin: A 28-amino-acid28\text{-amino-acid} peptide hormone produced primarily by the stomach mucosa. It acts as an endogenous ligand for the Growth Hormone Secretagogue Receptor (GHS-R).

      • Functions as a potent hunger signal in the gut-brain axis.

      • Acts directly on pituitary somatotrophs to promote GH release.

      • Stimulates hypothalamic GHRH release and suppresses somatostatin secretion, exerting a synergistic effect with GHRH on GH secretion.

Ghrelin interaction with GHRH and Somatostatin
  • Negative Feedback Loops:

    • Short-Loop Feedback: GH inhibits its own secretion by acting directly on the pituitary and hypothalamus.

    • Long-Loop Feedback: Circulating IGF-1 (derived mainly from the liver) exerts negative feedback by inhibiting anterior pituitary somatotrophs and hypothalamic GHRH neurons, while simultaneously stimulating hypothalamic somatostatin release.

Neural, Hormonal, and Physiological Modulators of Growth Hormone

  • Physiological and Nutritional Stimuli:

    • Amino Acids: Elevated plasma amino acids (e.g., following a protein-rich meal) strongly stimulate GH release to promote protein synthesis and tissue building.

    • Hypoglycemia: Decreased blood glucose levels trigger GH release as a counter-regulatory mechanism to raise blood glucose.

    • Fasting and Starvation: Sustained nutrient deprivation increases GH release to mobilize fat stores and conserve protein.

    • Physical Exercise: High-intensity physical activity acts as a potent physical stimulus for GH release.

    • Acute Short-Term Stress: Increases GH secretion to prepare metabolic substrates for acute physiological demand.

    • Sleep: Deep slow-wave sleep is a major physiological stimulant of GH release.

    • Sex Steroids (Estrogen and Puberty): Estrogen enhances GH secretion, leading to elevated peak GH amplitudes during puberty.

  • Inhibitory Factors:

    • Hyperglycemia: Elevated plasma glucose levels suppress GH secretion.

    • Free Fatty Acids (FFAs): Elevated circulating FFAs exert negative feedback to suppress GH release.

    • Aging: Serum GH levels progressively decrease with age (a phenomenon termed somatopause).

    • Chronic Stress and Glucocorticoid Excess: Prolonged exposure to high levels of cortisol or exogenous glucocorticoids suppresses the HPS axis and impairs growth.

  • Circadian Pattern and Sleep Dynamics:

    • GH secretion is highly pulsatile, exhibiting episodic secretory bursts separated by periods of undetectable serum levels.

    • In healthy young adults, approximately 60% to 70%60\%\text{ to }70\% of total daily GH secretion occurs during nocturnal sleep.

    • The primary peak in GH secretion occurs shortly after the onset of slow-wave sleep (Stage 3 and Stage 4 NREM sleep).

    • Sleep deprivation severely dampens or abolishes this primary nocturnal pulse.

    • In pathological states such as acromegaly, the normal circadian pulsatile rhythm is lost, resulting in persistently elevated baseline GH levels throughout the day and night.

Effect of sleep and sleep deprivation on GH secretion
  • Impact of Age and Sex:

    • Pubertal Peak: Daily mean GH concentration and pulse amplitude reach maximum values during the pubertal growth spurt (ages 13–15 years13\text{--}15\,\text{years}), correlating directly with peak growth velocity (cm/year\text{cm/year}).

    • Sexual Dimorphism: Females generally display higher mean plasma GH concentrations and larger pulse amplitudes than males due to estrogenic stimulation.

    • Age-Related Decline: Following early adulthood, overall GH secretion declines progressively with age. This decline is linked to age-related changes in body composition, including reduced lean muscle mass, decreased bone density, increased visceral adiposity, and diminished exercise tolerance.

    • Due to these dynamic variations, biochemical evaluations of serum GH and IGF-1 must always be interpreted using strict age- and sex-matched reference ranges.

GH pulse variations by age and sex

Growth Hormone Secretagogues and Molecular Receptor Signaling

  • G-Protein Coupled Receptor (GPCR) Pathways in Somatotrophs:

    • GHRH Receptor (GHRH-R):

      • Localization: Exclusively on pituitary somatotrophs.

      • Endogenous Ligand: GHRH.

      • G-Protein Coupling: GsG_s subunit.

      • Intracellular Signaling: Activation of adenylyl cyclase →\rightarrow elevation of intracellular cyclic adenosine monophosphate (cAMPcAMP) →\rightarrow activation of Protein Kinase A (PKA) →\rightarrow stimulation of GH gene transcription and exocytosis.

    • Growth Hormone Secretagogue Receptor (GHS-R):

      • Localization: Expressed on pituitary somatotrophs and hypothalamic GHRH neurons.

      • Endogenous Ligand: Ghrelin.

      • G-Protein Coupling: GqG_q subunit.

      • Intracellular Signaling: Activation of Phospholipase C (PLC) →\rightarrow generation of Inositol Trisphosphate (IP3IP_3) and Diacylglycerol (DAG) →\rightarrow mobilization of intracellular calcium ([Ca2+]i[Ca^{2+}]_i) →\rightarrow rapid exocytosis of preformed GH storage vesicles.

Receptor signaling pathways of GHRH-R and GHS-R
  • Pharmacological Application: Anamorelin:

    • Drug Class: Synthetic, orally active, non-peptide GHS-R agonist.

    • Mechanism of Action: Selectively binds GHS-R to mimic the hunger-stimulating and GH-releasing actions of endogenous ghrelin.

    • Therapeutic Indication: Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) in patients with advanced Non-Small Cell Lung Cancer (NSCLC), gastric cancer, pancreatic cancer, and colorectal cancer.

    • Clinical Evidence: Phase 3 clinical trials (ANAM 17-20 and ANAM 17-21, presented at the 2023 ESMO Annual Congress) demonstrated that daily oral anamorelin significantly increases total body weight, appetite, and lean muscle mass compared to placebo in NSCLC patients suffering from cachexia.

    • Pharmacokinetics: Features an extended biological half-life permitting convenient once-daily oral dosing.

Anamorelin binding to GHS-R and cachexia progressionMuscle wasting in cachexia

Structural Homology and the Insulin-Like Growth Factor (IGF) System

  • Molecular Structure and Homology of IGFs:

    • Insulin, IGF-1, and IGF-2 belong to a single gene superfamily of peptide hormones sharing high sequence homology.

    • Domain Structure:

      • Insulin: Consists of an A-chain (21 amino acids21\text{ amino acids}) and a B-chain (30 amino acids30\text{ amino acids}) connected by disulfide bridges. The intervening C-domain (31 amino acids31\text{ amino acids}) is enzymatically cleaved during proinsulin processing and released as C-peptide.

      • IGF-1: Single-chain peptide containing an A-domain (21 amino acids21\text{ amino acids}), B-domain (29 amino acids29\text{ amino acids}), an uncleaved C-domain (12 amino acids12\text{ amino acids}), and a unique short D-domain (8 amino acids8\text{ amino acids}).

      • IGF-2: Structure similar to IGF-1, containing B (29 AA29\text{ AA}), C (12 AA12\text{ AA}), A (21 AA21\text{ AA}), and D domains.

    • Homology Values:

      • Insulin B-domain vs. IGF-1 B-domain: 13/2913/29 sequence homology.

      • Insulin A-domain vs. IGF-1 A-domain: 11/2111/21 sequence homology.

      • IGF-1 vs. IGF-2 B-domains: 22/2922/29 sequence homology.

      • IGF-1 vs. IGF-2 A-domains: 18/2118/21 sequence homology.

      • IGF-1 vs. IGF-2 D-domains: 4/64/6 sequence homology.

Structural comparison of Insulin, IGF-1, and IGF-2
  • Receptor Homology and Cross-Reactivity:

    • Both the Insulin Receptor and the IGF-1 Receptor (IGF-1R) are heterotetrameric transmembrane complexes (α2β2\alpha_2\beta_2) belonging to the Receptor Tyrosine Kinase (RTK) family.

    • Binding Affinities:

      • Insulin binds the Insulin Receptor with high affinity and the IGF-1R with low affinity.

      • IGF-1 binds IGF-1R with high affinity and the Insulin Receptor with low affinity.

    • Cross-Reactivity Effects: Direct intravenous or high-dose administration of exogenous IGF-1 can induce acute hypoglycemia by activating insulin receptors and insulin-IGF hybrid receptors in skeletal muscle to stimulate glucose uptake.

Receptor homology between Insulin Receptor and IGF-1 Receptor

Circulating Binding Proteins: GHBP and IGFBPs

  • Growth Hormone Binding Protein (GHBP):

    • Derived from enzymatic cleavage of the extracellular domain of the cell-surface Growth Hormone Receptor (GHR) in the liver.

    • Circulates in blood, binding GH to form a reservoir that buffers plasma GH fluctuations.

  • Insulin-like Growth Factor Binding Proteins (IGFBP-1 to IGFBP-6):

    • A family of six distinct high-affinity carrier proteins (IGFBP-1 through IGFBP-6) that regulate circulating IGF activity.

    • IGFBP-3: The predominant circulating binding protein, carrying approximately 90%90\% of all serum IGF-1.

    • Ternary Complex Structure: In circulation, IGF-1 and IGFBP-3 bind an Acid-Labile Subunit (ALS) to form a high-molecular-weight 150 kDa150\,\text{kDa} ternary complex.

    • Distribution: Approximately 98% to 99%98\%\text{ to }99\% of circulating IGF-1 is tightly bound within protein complexes, leaving only 1% to 2%1\%\text{ to }2\% as free, bioactive peptide.

    • Physiological Significance:

      • Half-Life Extension: Unbound free IGF-1 in serum is rapidly cleared by renal filtration with a half-life of only 4.5 to 20 minutes4.5\text{ to }20\,\text{minutes}. When bound in the 150 kDa150\,\text{kDa} ternary complex, its half-life extends to 12 to 15 hours12\text{ to }15\,\text{hours}.

      • Activity Modulation: Regulates tissue delivery and receptor access, acting as a vascular reservoir that prevents systemic hypoglycemia.

IGFBPs and the 150kDa ternary complex

Physiological Theories of Growth Hormone Action

  • Somatomedin Hypothesis (Outdated Concept):

    • Formulated based early on in vitro observations suggesting that GH possessed no intrinsic growth-promoting activity directly on target tissues.

    • Postulated that GH acted exclusively as an endocrine trigger for hepatic synthesis of intermediary secondary hormones called "somatomedins" (IGF-1), which then entered circulation to drive systemic tissue growth.

  • Dual-Effector Theory (Current Accepted Model):

    • States that GH and IGF-1 act in a coordinated, distinct, and sequential manner directly at the target tissue site to drive linear growth.

    • Distinct Role of GH: GH binds directly to GHR on progenitor cells (e.g., prechondrocytes in the epiphyseal growth plate), driving their differentiation into functional early chondrocytes.

    • Role of Local and Systemic IGF-1:

      • GH-induced differentiation stimulates local chondrocytes to express their own IGF1 genes and IGF-1 receptors.

      • Locally produced IGF-1 acts via autocrine and paracrine signaling to stimulate clonal expansion, rapid proliferation, and hypertrophy of these chondrocytes.

      • Endocrine (hepatic) IGF-1 supplements local paracrine activity, but local production driven directly by GH is required for full bone growth.

Dual-Effector Theory mechanism in bone cartilage

Growth-Promoting Effects on Bone and Extra-Skeletal Tissues

  • Effects on Extra-Skeletal Soft Tissues:

    • Increases total cell size (hypertrophy) and total cell number (hyperplasia / mitosis).

    • Stimulates cellular uptake of amino acids and accelerates nuclear transcription and translation (DNA, RNA, and protein synthesis\text{DNA, RNA, and protein synthesis}).

    • Promotes organ enlargement and muscle hypertrophy, increasing overall lean muscle mass.

Direct and indirect effects of GH and IGF-1
  • Effects on Bone Growth and Development:

    • Endochondral (Linear) Longitudinal Growth:

      • Occurs specifically at the epiphyseal growth plate prior to epiphyseal closure at the end of puberty.

      • Zone of Resting Chondrocytes: GH directs differentiation of precursor reserve cells into chondrocyte lineage.

      • Zone of Proliferation: Local and endocrine IGF-1 triggers rapid cell division of chondrocytes arranged in columns.

      • Zone of Hypertrophy: Chondrocytes enlarge significantly and secrete extracellular matrix proteins (predominantly collagen).

      • Calcification and Ossification: Osteoclasts reabsorb degraded cartilage matrix, while osteoblasts lay down new bone matrix on top of calcified cartilage at the diaphyseal side, extending total bone length.

    • Appositional (Radial) Growth:

      • Promotes widening and thickening of bone diameters.

      • GH and IGF-1 stimulate periosteal osteoblasts to deposit new compact bone layers onto the outer bone surface.

      • Appositional growth continues throughout adult life, even after epiphyseal plates fuse and longitudinal growth ceases.

Bone growth dynamics at the epiphyseal plate

Direct Metabolic Actions of Growth Hormone and Energy Integration

  • Lipolytic Effect (Fat Mobilization):

    • GH acts directly on adipocytes to stimulate lipolysis, activating hormone-sensitive lipase (HSL) via cyclic AMP and protein kinase signaling.

    • Breaks down stored triacylglycerides (TG) into free fatty acids (FFAs) and glycerol, releasing them into circulation.

    • Shifts bodily metabolism away from carbohydrate usage toward lipid oxidation as the primary energy source.

Lipolytic pathway in adipocyte
  • Protein-Sparing Effect:

    • By shifting energy production to FFA oxidation, GH prevents amino acid catabolism.

    • Promotes amino acid transport across plasma membranes and accelerates cellular protein deposition.

  • Anti-Insulin (Diabetogenic) Effect:

    • Antagonizes peripheral insulin actions, inducing a state of peripheral insulin resistance.

    • Decreases glucose uptake and utilization in skeletal muscle and adipose tissue.

    • Increases hepatic output of glucose via enhanced gluconeogenesis.

    • Net effect: Elevates blood glucose levels, conserving glucose for obligate, glucose-dependent metabolic tissues (e.g., central nervous system/brain, erythrocytes, and the ocular lens).

  • Nutrient-Dependent Metabolic Integration:

    • High Protein Intake (Well-Fed State): Stimulates simultaneous secretion of both GH and Insulin. High insulin permits optimal hepatic IGF-1 synthesis. Result: High GH + High Insulin + High IGF-1 →\rightarrow Enhanced amino acid uptake, maximal protein synthesis, and active tissue growth.

    • High Carbohydrate Intake: Increases blood glucose and stimulates high insulin, which suppresses GH secretion. Result: Low GH + High Insulin + Low IGF-1 →\rightarrow Storage of excess calories as fat/glycogen; protein synthesis and longitudinal growth are minimal.

    • Fasting / Starvation State: Hypoglycemia suppresses insulin secretion while stimulating high GH secretion. Low baseline insulin impairs hepatic IGF-1 synthesis despite elevated GH. Result: High GH + Low Insulin + Low IGF-1 →\rightarrow Absence of tissue growth; direct metabolic actions of GH predominate (fat mobilization via lipolysis, glucose sparing, preservation of muscle protein).

Differential regulation of GH, Insulin, and IGF-1 by nutritional status

Pathophysiology of Growth Hormone Excess: Gigantism and Acromegaly

  • Gigantism:

    • Definition: Severe hypersecretion of GH occurring during childhood before the closure of epiphyseal growth plates.

    • Clinical Presentation: Exaggerated, symmetrical linear longitudinal growth resulting in tall stature without significant bone distortion. Individuals can reach heights exceeding 250 cm250\,\text{cm}.

  • Acromegaly:

    • Definition: Chronic hypersecretion of GH occurring during adulthood after the complete fusion of epiphyseal growth plates.

    • Clinical Features:

      • Acral Overgrowth: Progressive enlargement of the hands and feet, evidenced by increasing shoe and ring sizes.

      • Craniofacial Changes: Coarsening of facial features, frontal bone bossing, supraorbital ridge bulging, enlargement of the nose and lips, macroglossia (tongue enlargement), and mandible overgrowth leading to prognathism (underbite) and interdental tooth separation (diastema).

      • Dermatological Manifestations: Increased skin thickness, skin tags, and severe hyperhidrosis (excessive sweating).

Clinical features of Acromegaly
  • Systemic Complications and Morbidity:

    • Cardiorespiratory System: Concentric biventricular hypertrophy, acromegalic cardiomyopathy, cardiac arrhythmias, valvulopathies, severe hypertension, obstructive sleep apnea (due to soft-tissue pharyngeal collapse), and heart failure.

    • Metabolic Complications: Severe insulin resistance, glucose intolerance, secondary type 2 diabetes mellitus, and atherogenic dyslipidemia.

    • Musculoskeletal System: Osteophytosis, cartilage hypertrophy leading to severe large-joint arthropathy, carpal tunnel syndrome (median nerve compression), and back pain.

    • Neoplasia Risks: Increased incidence of premalignant gastrointestinal colon polyps, elevated risk of colorectal carcinoma, renal cell carcinoma, and thyroid nodular disease/cancer.

Systemic complications and morbidity in Acromegaly
  • Etiology:

    • Primary Pituitary Adenoma (∼95%\sim 95\% of cases): Monoclonal benign somatotroph adenomas of the anterior pituitary.

      • Microadenomas: Diameter <10 mm< 10\,\text{mm}.

      • Macroadenomas: Diameter ≥10 mm\ge 10\,\text{mm}.

    • Extra-Pituitary Causes (∼5%\sim 5\% of cases): Ectopic secretion of GHRH or GH from neuroendocrine tumors (e.g., bronchial carcinoids, pancreatic islet cell tumors, small cell lung cancer).

Etiology of Growth Hormone excess
  • Tumor Mass Effects: Bitemporal Hemianopia:

    • As a pituitary macroadenoma grows superiorly out of the sella turcica, it compresses the overlying optic chiasm.

    • Specifically damages decussating nasal retinal nerve fibers, which transmit visual information from the temporal fields.

    • Clinical Result: Bitemporal hemianopia (loss of the outer temporal halves of the visual field in both eyes).

    • Note: This visual field defect is a mechanical mass effect of the tumor itself, not an action of excess GH hormone.

Optic chiasm compression and bitemporal hemianopia

Diagnostic Workup and Biochemical Evaluation of Acromegaly

  • Step 1: First-Line Screening with Serum IGF-1:

    • Random plasma GH levels are not recommended for primary screening due to the short half-life (∼20 minutes\sim 20\,\text{minutes}) and pulsatile nature of GH secretion.

    • Serum IGF-1 serves as the primary screening tool. IGF-1 levels are stable across the day due to carrier protein binding (half-life 12–15 hours\text{half-life } 12\text{--}15\,\text{hours}) and integrate cumulative GH activity.

    • Serum IGF-1 concentrations must be elevated above age- and sex-matched reference limits to suggest disease. A normal IGF-1 level excludes active acromegaly.

  • Step 2: Confirmatory Oral Glucose Tolerance Test (OGTT):

    • Procedure: Patient ingests an oral solution containing 75 g75\,\text{g} of glucose after an overnight fast, followed by serial plasma GH and glucose measurements.

    • Physiological Response in Healthy Individuals: Oral glucose triggers hyperglycemia, which stimulates hypothalamic somatostatin and suppresses ghrelin, suppressing serum GH to undetectable levels (<1 μg/L< 1\,\mu\text{g/L} or <2 mU/L< 2\,\text{mU/L} within 1 to 2 hours1\text{ to }2\,\text{hours}).

    • Diagnostic Findings in Acromegaly: Pituitary somatotroph adenomas operate outside normal negative feedback mechanisms. A lack of GH suppression (GH remaining ≥1 μg/L\ge 1\,\mu\text{g/L}) confirms acromegaly.

    • Paradoxical Rise: In approximately 1/31/3 of acromegalic patients, oral glucose causes an aberrant, paradoxical rise in serum GH levels. This occurs due to ectopic expression of Glucose-Dependent Insulinotropic Polypeptide Receptors (GIPR) on somatotroph adenoma cells. Ingested glucose stimulates intestinal K-cells to release GIP, which binds aberrant adenoma GIPRs to trigger cAMPcAMP signaling and GH exocytosis.

OGTT GH suppression curves in normal vs acromegalyMechanism of paradoxical GH rise via GIP receptor ectopic expression
  • Step 3: Imaging and Anatomical Localization:

    • Following biochemical confirmation, a targeted pituitary Magnetic Resonance Imaging (MRI) with contrast is performed to visualize adenoma presence, exact dimensions (micro-vs. macroadenoma\text{micro-} \text{vs. macroadenoma}), and invasion into adjacent structures (e.g., optic chiasm, cavernous sinus).

    • If pituitary MRI shows normal tissue or diffuse hyperplasia, chest and abdominal Computed Tomography (CT) scans are ordered to locate ectopic GHRH- or GH-secreting neuroendocrine tumors.

Diagnostic algorithm flowchart for Acromegaly

Clinical Management and Pharmacotherapy of Growth Hormone Excess

  • Surgical Management (First-Line Treatment):

    • Transsphenoidal Pituitary Surgery: Surgical resection of the adenoma via the transsphenoidal route is the primary treatment for most acromegalic patients.

    • Achieves immediate biochemical normalization and relieves local tumor mass effects.

    • Surgical failure rates exceed 10% to 30%10\%\text{ to }30\%, particularly in patients with large, invasive macroadenomas, requiring secondary medical or radiation intervention.

Overview of management modalities for acromegaly
  • Pharmacological Treatments:

    • Somatostatin Receptor Ligands (SRLs / Somatostatin Analogs):

      • Examples: Octreotide, Octreotide LAR, Lanreotide, Lanreotide Autogel.

      • Mechanism: Bind somatostatin receptors (primarily SSTR2 and SSTR5) on somatotroph cells, inhibiting adenylyl cyclase, lowering intracellular cAMPcAMP, and directly suppressing GH secretion while causing tumor shrinkage.

    • Dopamine Receptor Agonists:

      • Examples: Cabergoline, Bromocriptine.

      • Mechanism: Act on D2D_2 dopamine receptors expressed on adenoma cells to suppress GH release.

      • Indication: Particularly useful in mixed lactotrope-somatotrope adenomas that co-secrete GH and prolactin.

    • Growth Hormone Receptor Antagonist:

      • Example: Pegvisomant.

      • Mechanism: A genetically engineered analog of human GH containing structural mutations. Binds to Site 1 of the cell-surface GHR with enhanced affinity but contains amino acid substitutions at Site 2 that disrupt functional receptor dimerization and prevent downstream JAK2/STAT5 signaling. Blockade of hepatic GHRs prevents IGF-1, IGFBP-3, and ALS synthesis.

      • Biochemical Profile: Rapidly lowers serum IGF-1 levels to normal range, although circulating immunoreactive GH levels remain elevated due to loss of IGF-1 negative feedback on the pituitary.

Pharmacological mechanisms of SRLs, Dopamine Agonists, and GH Receptor Antagonists
  • Radiotherapy:

    • Reserved as a secondary or tertiary option for patients with persistent disease following failed surgery and pharmacological resistance.

    • Drives slow, progressive reduction of GH levels over years; high risk of late-onset hypopituitarism requiring lifelong hormone replacement.

Growth Hormone Deficiency, Laron Syndrome, and Clinical Interventions

  • Growth Hormone Deficiency (GHD / Pituitary Dwarfism):

    • Etiology: Insufficient GH synthesis or secretion due to congenital lesions, genetic mutations (e.g., PROP1, GH1), pituitary tumors, trauma, or radiation.

    • Pediatric Presentation: Proportional short stature, delayed bone age, microphallus, and tendency toward fasting hypoglycemia.

    • Adult Presentation: Increased visceral adiposity, decreased skeletal muscle mass (sarcopenia), osteopenia/osteoporosis, reduced cardiac ejection fraction, hypercholesterolemia, and impaired quality of life.

    • Diagnostic Stimulation Test: Insulin Tolerance Test (ITT). Intravenous regular insulin (0.05–0.15 U/kg0.05\text{--}0.15\,\text{U/kg}) is administered to induce acute hypoglycemia (blood glucose <2.2 mmol/L\text{blood glucose } < 2.2\,\text{mmol/L} or <40 mg/dL< 40\,\text{mg/dL}). Severe hypoglycemia acts as a central stimulus to evaluate HPS axis reserve. Normal individuals demonstrate a sharp surge in plasma GH (>5–10 μg/L> 5\text{--}10\,\mu\text{g/L}) and cortisol; a failure of GH to rise confirms GHD.

    • Treatment: Recombinant human growth hormone (rhGH / Somatropin) daily subcutaneous injections promote linear growth velocity and target height attainment if initiated prior to pubertal epiphyseal fusion.

Insulin Tolerance Test response for GH reserve evaluation
  • Laron Syndrome (Growth Hormone Insensitivity):

    • Etiology: Rare autosomal recessive disorder caused by loss-of-function mutations in the cell-surface Growth Hormone Receptor (GHR) gene.

    • Hormonal Profile: High or normal circulating serum GH concentrations combined with markedly low serum IGF-1 and IGFBP-3 levels.

    • Pathophysiology: Defective GHR prevents liver responsiveness to GH, abolishing IGF-1 production. Lack of IGF-1 removes negative feedback inhibition, resulting in compensatory hypersecretion of pituitary GH.

    • Treatment: Exogenous rhGH therapy is completely ineffective because receptors are non-functional. Treatment requires recombinant human IGF-1 (mecasermin) daily subcutaneous injections.

    • Validation of Dual-Effector Theory: Linear growth velocity recovery in mecasermin-treated Laron patients remains lower than growth velocity achieved in rhGH-treated pituitary dwarfism patients. This clinical finding confirms that direct GH stimulation on progenitor prechondrocytes is necessary for IGF-1 to exert its full tissue-building effect.

Normal HPS axis vs. Laron Syndrome receptor insensitivity
  • Comparison of Growth Disorders:

Disorder

Serum GH Level

Serum IGF-1 Level

Primary Anatomic Lesion Site

Effective First-Line Therapy

Pituitary Dwarfism (GHD)

Low (↓\downarrow)

Low (↓\downarrow)

Hypothalamus / Pituitary somatotrophs

Recombinant Human GH (rhGH)

Laron Syndrome

Elevated or Normal (↑\uparrow)

Low (↓\downarrow)

Target Tissue GH Receptor (GHR)

Recombinant Human IGF-1 (Mecasermin)

Gigantism (Pediatric)

Elevated (↑\uparrow)

Elevated (↑\uparrow)

Pituitary Somatotroph Adenoma

Transsphenoidal Surgery / SRLs

Acromegaly (Adult)

Elevated (↑\uparrow)

Elevated (↑\uparrow)

Pituitary Somatotroph Adenoma

Transsphenoidal Surgery / SRLs

Spectrum of GH disorders diagram
  • Indications, Abuse, and Adverse Effects of Exogenous HGH:

    • Approved Indications:

      • Children: Pediatric GHD, Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency, Idiopathic Short Stature (ISS).

      • Adults: Adult GHD, Short Bowel Syndrome, Severe HIV/AIDS-associated muscle wasting.

    • Illegal Use / Misuse: Anti-aging therapy, body-building muscle hypertrophy, cosmetic weight loss, and athletic performance enhancement (strictly prohibited by World Anti-Doping Agency [WADA]).

    • Adverse Effects of Exogenous GH Misuse: Peripheral fluid retention (edema), carpal tunnel syndrome, arthralgias, gynecomastia, severe insulin resistance, hyperinsulinemia, increased long-term risk of malignancies (specifically prostate and colorectal cancer).

Clinical Quiz & Self-Assessment

  • Question 1:

    • Scenario: A 10-year-old10\text{-year-old} boy presents with severe short stature. Laboratory investigations reveal markedly elevated serum GH (↑↑\uparrow\uparrow) and severely reduced serum IGF-1 (↓↓\downarrow\downarrow).

    • Options: A. Pituitary dwarfism | B. Hypothyroidism | C. Laron syndrome | D. Gigantism

    • Correct Answer: C. Laron syndrome

    • Rationale: High serum GH paired with low serum IGF-1 indicates peripheral target organ resistance to GH, caused by loss-of-function mutations in the GH receptor. Pituitary dwarfism would demonstrate low serum GH levels.

  • Question 2:

    • Scenario: Two pediatric patients are evaluated for growth failure:

      • Patient A: Low serum GH (↓\downarrow), Low serum IGF-1 (↓\downarrow).

      • Patient B: Elevated serum GH (↑\uparrow), Low serum IGF-1 (↓\downarrow).

    • Question: Which patient has a primary pituitary defect?

    • Options: A. Patient A | B. Patient B | C. Both | D. Neither

    • Correct Answer: A. Patient A

    • Rationale: Patient A displays failure of the anterior pituitary somatotrophs to synthesize and secrete GH, resulting in secondary deficiency of liver-derived IGF-1 (Pituitary Dwarfism). Patient B has intact pituitary GH secretion but displays end-organ resistance (Laron Syndrome).